Conferences and congresses

Conferences and congresses
Anaferon for children
An innovative drug for the treatment and prevention of influenza. For sale in Mexico.
16 Congresses and conferences

Anaferon for children

An innovative drug for the treatment and prevention of influenza. For sale in Mexico.
Information about the preparation

Date
Conference name
Address
Thesises

June 24-28,  2003

6th congress of the European Association for Clinical Pharmacology and Therapeutics
Istanbul, Turkey
Martyushev-Poklad A.V., Drinevskiy V.P., Osidak L.V., Dugina J.I., Kotelnikova M.P., Sergeeva S.A., Epstein O.I. Anaferon – A Novel Therapeutic For Influenza in Children: Clinical Efficacy and Immunomodulation. // Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. – Istanbul. – June 24-28, 2003. – P.99
May 1-4, 2004
14th European Congress of Clinical Microbiology and Infectious Diseases.
Prague, Czech Republic
Martyushev-Poklad A.V., Uchaikin V.F., Kotelnikova M.P., Dugina J.L., Epstein O.I., Sergeeva S.A. A novel antiviral based on oral antibodies: clinical benefits in paediatric upper respiratory infections. // Clinical Microbiology and Infection. – 2004. – Vol.10, Suppl.3. – P.125-126 (14th European Congress of Clinical Microbiology and Infectious Diseases. – Prague, Czech Republic. – May 1-4, 2004.).
May 26-28, 2004
22nd Annual Meeting of the European society for pediatric infections deseases
Tampere, Finland.
Thesis 1  

Martyushev-Poklad A.V., Uchaikin V.F., Drinevsky V.P., Petrov V.I., Osidak L.V., Dugina J.L., Epstein O.I., Sergeeva S.A. Anaferon - A novel Antiviral Agent: Controlled Trials of Efficacy in Pediatric Upper Respiratory Infections. // 22nd Annual Meeting of the European society for paediatric infectious diseases. – Tampere, Finland. – May 26-28, 2004. – P.11

Thesis 2

Martyushev-Poklad A.V., Uchaikin V.F., Drinevsky V.P., Osidak L.V., Dugina J.L., Epstein O.I., Sergeeva S.A. Prophylaxis of Pediatric Upper Respiratory Infections with Anaferon: Controlled Clinical Trial. // 22nd Annual Meeting of the European society for pediatric infectious diseases. – Tampere, Finland. – May 26-28, 2004. – P.111
August 1-6, 2004
8th World Congress on Clinical Pharmacology & Theurapetics Incorporating the Annual Scientific Meeting of ASCEPT
Brisbane (Australia)

Sergeeva S.A., Martyushev-Poklad A.V., Petrov V.I., Epstein O.I., Dugina J.L. Anaferon, oral anti-interferon gamma antibodies for treatment and prophylaxic of viral infections. // Clinical and Experimental Pharmacology and Physiology. – 2004. – Vol.31, Suppl.1. – A.114 (8th World Conference on Clinical Pharmacology and Therapeutics. Incorporating the Annual Scientific Meeting of ASCEPT. – Brisbane, Australia. – August 1-6, 2004.).

September 1-4, 2005
4th World Congress of the World community of pediatric infectious diseases
Warsaw, Poland

Thesis 1

Martyushev-Poklad A.V., Kudin M.V., Dyldina N.V., Dugina J.L., Kachanova M.V., Epstein O.I., Sergeeva S.A. A novel therapeutic for treatment of varicella: peroaral anti-interferon gamma antibodies. // 4th World congress of the world society for pediatric infectious diseases - WSPID. – Warsaw, Poland. – September 1-4, 2005. – P.144

Thesis 2

Martyushev-Poklad A.V., Uchaikin V.F., Drinevsky V.P., Osidak L.V., Dyldina N.V., Dugina J.L., Epstein O.I., Sergeeva S.A. A novel anti-interferon gamma antibody therapeutic: clinical benefits in paediatric viral upper respiratory tract infection. // 4th World congress of the world society for pediatric infectious diseases – WSPID. - Warsaw, Poland. – September 1-4, 2005. – P.178

July 2-7, 2006
15th World Congress of Pharmacology
Beijing, China

Martyushev-Poklad A., Sergeeva S., Dugina J., Epstein O. Anaferon, an oral anti-interferon gamma antiviral: clinical efficacy in common paediatric viral infections. // Acta Pharmacologica Sinica. – 2006. – Vol.27, Suppl.1. – P.52 (15th World Congress of Pharmacology. – Beijing, China. – July 2-7, 2006.).

August 25-30, 2007
25th International Congress of Pediatrics
Athens, Greece

Thesis 1

Dugina Y., Tarasov S., Elfimova U., Martyushev-Poklad A., Epstein O., Sergeeva S. Clinical efficacy of anaferon, a novel oral antibody therapeutic, in pediatric acute viral gastroenteritis. // 25th International Congress of Pediatrics «for the health and well-being of our children». – Athens, Greece. – August 25-30, 2007. – PP0526

Thesis 2

Tarasov S., Dugina Y., Elfimova U., Martyushev-Poklad A., Epstein O., Sergeeva S. Anaferon in pediatric febrile viral infections: a brief review of the results of clinical trials in Russia. // 25th International Congress of Pediatrics «for the health and well-being of our children». – Athens, Greece. – August 25-30, 2007. – PP0531
July 13-17, 2008
ЕPHAR 2008
Manchester, England
Tarasov S., Dugina J., Sergeeva S., Epstein O. Oral antibody to interferon gamma in ultra low doses: clinical efficacy and interferon stimulation in patients with upper respiratory viral infections. // Fundamental & Clinical Pharmacology. – 2008. – Vol.22, Suppl.2. – P.37 (EPHAR 2008 Congress. Hosted by the British Pharmacological Society. – Manchester, UK. – July 13-17, 2008.).
September 12-16, 2009
19th Annual Congress European Respiratory
Vienna, Austria
Zaplatnikov A., Korovina N., Burtseva E., Isaeva E., Zak I. Clinical and virusological effectiveness study of ultralow doses of antibodies to interferon-gamma in treatment of acute respiratory viral influena in children. // European Respiratory Journal. – 2009. – Vol.34, Suppl.53. – P.719s (19th ERS Annual Congress. – Vienna, Austria. – September 12-16, 2009.).
April 10-13, 2010
20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Vienna, Austria
Tarasov S., Zarubaev V., Tafani J., Dugina J., Sergeeva S., Epstein O. Antibodies to interferon-gamma in ultra-low doses: a new option for pandemic influenza. // Clinical Microbiology and infection. – 2010. – Vol.16, Suppl.2. – S.305. (20th European Congress of Microbiology and Infectious Diseases. – Vienna, Austria. – April 10-13, 2010.).
September 1-5, 2012
22th Annual Congress European Respiratory
Vienna, Austria

Thesis 1

Zaplatnikov A., Korovina N., Zakharova I., Burtseva E., Mingalimova G., Zaplatnikova L., Zak I., Shamrai L. Evaluation of efficacy of interferon inducer in treatment of the recurrent acute respiratory viral infections in children. // European respiratory journal. – 2012. – Vol.40, Suppl.56. – P.332s-333s (22nd Annual Congress. – Vienna. – September 1-5, 2012.).

Thesis 2

Zaplatnikov A., Korovina N., Zakharova I., Burtseva E., Mingalimova G., Zaplatnikova L., Zak I., Shamrai L. Prevention of the recurrent acute respiratory viral infections in children. // European respiratory journal. – 2012. – Vol.40, Suppl.56. – P.467s (22nd Annual Congress. – Vienna. – September 1-5, 2012.).
April 27-30, 2013
23th European Congress of Clinical Microbiology and Infectious Diseases
Berlin, Germany
Lobzin Y., Volzhanin V.M., Babachenko I.V. Antiviral efficacy and interferon inducing activity of the release-active antibodies to interferon-gamma in children with influenza: results of randomized comparative (vs oseltamivir) parallel-group clinical study, season 2012-2013. // European Congress of Clinical Microbiology and Infectious Diseases. – Berlin, Germany. – April 27-30, 2013. – LB2955
May 28-June 1, 2013
31st Annual Meeting of the European Society for Paediatric Infectious Diseases
Milan, Italy

Thesis 1

Gorelov A., Ploskireva A. Evaluation of efficacy of interferon inducer in treatment of acute gastroenteritis in children. // 31st Annual Meeting of the European society for paediatric infectious diseases. – Milan, Italy. – May 28-June 1, 2013.


Thesis 2


Gorelov A. Evaluation of efficacy of interferon inducer in prevention of the nosocomial gastrointestinal infections in children. // 31st Annual Meeting of the European society for paediatric infectious diseases. – Milan, Italy. – May 28-June 1, 2013.


Thesis 3


Zaplatnikov A. Evaluation of efficacy of interferon inducer in treatment of the recurrent acute respiratory viral infections in children. // 31st Annual Meeting of the European society for paediatric infectious diseases. – Milan, Italy. – May 28-June 1, 2013.


Thesis 4


Zaplatnikov A. Prevention of the recurrent acute respiratory viral infections in children. // 31st Annual Meeting of the European society for paediatric infectious diseases. – Milan, Italy. – May 28-June 1, 2013.
August 24-29, 2013
27th Congress of the Pediatric Association 2013
Melbourne, Australia

Andrianova E.N. The efficacy and safety of use of Anaferon for children in the treatment of influenza and other acute respiratory viral infections in children. // 27th Congress of the Pediatric Association 2013. – Melbourne, Australia. - August 24-29, 2013. – Abstract.

September 7-11, 2013
ERS Annual Congress
Barselona, Spain

Thesis 1

Kondiurina E. Prevention of the recurrent acute respiratory viral infections and virus-induced exacerbation of bronchial asthma in children. // ERS Annual Congress, September 7-11, 2013.- Barselona, Spain. Abstract.

Thesis 2

Kondiurina E.The efficacy of multiple use of interferon-γ inducer in treatment of recurrent acute respiratory viral infections in children with bronchial asthma. // ERS Annual Congress, September 7-11, 2013.- Barselona, Spain. Abstract.
Jily 13-18, 2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Tarasov S., Gorbunov E., Myslivets M., Rodionova N., Epstein O. NOVEL
ANTIBODY-BASED BIOTECHNOLOGICAL APPROACH OF INFLUENZA MANAGEMENT:
SUMMARY OF PRECLINICAL AND CLINICAL STUDIES. // 17th World Congress of
Basic and Clinical Pharmaclogy. – Cape Town, South Africa. – Jily 13-18,
2014. – Vol.155, Supl.1. – P.230
Rengalin
Rengalin® is a treatment for non-productive and productive cough in adults and children from 3 years of age.
2 Congresses and conferences

Rengalin

Rengalin® is a treatment for non-productive and productive cough in adults and children from 3 years of age.
Information about the preparation

Date
Conference name
Address
Thesises
June 22-26  2013
World Allergy & Asthma Congress – 2013
Milan, Italy
Babakhin A., Shershakova N., Shilovskiy I., Kozmin L., Tarasov S., Sekirina M., Gorbunov E., Epstein O., Khaitov M. Efficacy of a mixture of release-active rabbit polyclonal antibodies to histamine, bradykanin and morphin in the treatment of mouse model of allergic asthma. // World Allergy & Asthma Congress. – Milan, Italy. – June 22-26, 2013. – Abstract 60
July 13-18 2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Myslivetc M., Tarasov S., Khaitov M., Epstein O. MANAGEMENT OF
ALLERGEN-INDUCED BRONCHIAL ASTHMA AND VIRUS-INDUCED ASTHMA EXACERBATION
USING RELEASE-ACTIVE RABBIT POLYCLONAL ANTIBODIES. // 17th World
Congress of Basic and Clinical Pharmaclogy. – Cape Town, South Africa. –
Jily 13-18, 2014. – Vol.155, Supl.1. – P.345
Ergoferon
Ergoferon® has an enhanced potency owing to the combination of antiviral, anti-inflammatory and antihistamine effects.
1 Congresses and conferences

Ergoferon

Ergoferon® has an enhanced potency owing to the combination of antiviral, anti-inflammatory and antihistamine effects.
Information about the preparation

Date
Conference name
Address
Thesises
June 6-10  2015
European Acodemy of Allergy and Clinical Immunology Congress
Barcelona, Spain
Shilovskiy I., Shershakova N., Prozorova M., Khaitov M., Grechenko V., Nikiforova M., Yakovleva N., Borshcheva A., Tarasov S., Emelyanova A. RSV-specific antiviral activity of release-active polyclonal antibodies to interferon gamma, CD4 receptor and histamine in vitro. // Allergy. – 2015. – Vol.70, Suppl.S101. - P.403 (European Acodemy of Allergy and Clinical Immunology Congress. – Barcelona, Spain. – June 6-10, 2015)
Tenoten for children
Tenoten for children® is the only anti-anxiety drug designed specifically for pediatric patients taking in account the peculiarities of children's mental health.
2 Congresses and conferences

Tenoten for children

Tenoten for children® is the only anti-anxiety drug designed specifically for pediatric patients taking in account the peculiarities of children's mental health.
Information about the preparation

Date
Conference name
Address
Thesises
February 27-March 2, 2010
18th European Congress of Psychiatry
Munich, Germany
Kheyfets I., Chutko L., Surushkina S., Dugina J., Kachanova M., Sergeeva S., Epstein O. Clinical efficacy of Tenoten for children in treatment of attention dificit and hyperactivity disorder. // European Psychiatry. – 2010. – Vol.25, Suppl.1. – P01-219. (18th European Congress of Psychiatry. – Munich, Germany. – February 27-March 2, 2010.).
August 24-29, 2013
27th Congress of the Pediatric Association 2013
Melbourne, Australia
Andrianova E.N. The efficacy of Tenoten for kids in the treatment of autonomic sinus node disfunction in children. // 27th Congress of the Pediatric Association 2013. – Melbourne, Australia. - August 24-29, 2013. – Abstract.
Tenoten
Tenoten® is an anti-anxiety drug with stress protective activity.
7 Congresses and conferences

Tenoten

Tenoten® is an anti-anxiety drug with stress protective activity.
Information about the preparation

Date
Conference name
Address
Thesises
July 2-7  2006
15th World Congress of Pharmacology
China

Epstein O., Dugina J., Voronina T., Martyushev-Poklad A., Kheyfets I., Sergeeva S. Oral anti – S100 protein antibodies - a novel anxiolytic with antidepressant and neuroprotective potential. // Acta Pharmacologica Sinica. – 2006. – Vol.27, Suppl.1. – P.75 (15th World Congress of Pharmacology. – Beijing, China. – July 2-7, 2006.).

September 16-20  2006
19th ECNP Congress
Paris, France
Dugina J.L., Kheifez I.A., Martyushev-Poklad A.V., Voronina T.A., Molodavkin G.M., Epstein O.I., Sergeeva S.A. Anti-S100 antibodies ameliorate haloperidol-induced catalepsy and do not change the activity of haloperidol in apomorphine – induced stereotypy. // European Neuropsychopharmacology. – 2006. – Vol.16, Suppl.4. – S.436-437 (19th ECNP Congress. – Paris, France. – September 16-20, 2006.).
October 5-7  2006
Collegium Internationale Neuro-Psycho-pharmacologicum (CINP)
Tallinn

Kheyfets I.A., Voronina T.A., Dugina Y.L., Martyushev-Poklad A.V., Sergeeva S.A., Epstein O.I. Protective effects of ultra-low doses antibodies to S-100 protein in experimental model of scopolamine – induced amnesia. // Collegium Internationale Neuro-Psychopharmacologicum (CINP). – Tallin, Estonia. – October 5-7, 2006. – P.43 

October 13-17  2007
20th ECNP Congress
Vienna, Austria

Dugina Y.L., Voronina T.A., Molodavkin G.M., Kheifets I.A., Borodavkina M.V., Epstein O.I., Sergeeva S.A. Anti-S100 antibodies modulate locomotor activity and exploratory behaviour of immature rats. // European Neuropsychopharmacology. – 2007. – Vol.17, Suppl.4. – S.571. (20th ECNP Congress. – Vienna, Austria. – October 13-17, 2007.).

September 20-2  2008
XIV World Congress of Psychiatry
Prague, Czech Republic
Kheyfets I.A., Dugina J.L., Sabanov L.V., Sergeeva S.A., Epstein O.I. Tenoten in treatment of anxiety in patients with neurologic disorders. // Česka a Slovenská Psychiatrie. – 2008. – Vol.104, Suppl.2. – P.1191. (XIV World Congress of Psychiatry. – Prague, Czech Republic. – September 20-25, 2008.).
August 30 - September 3  2008
21st European Meeting on Hypertension and Cardiovascular Prevention
Milan, Italy

Poponina T.M., Poponina Y.S., Gunderina K.I. Treatment of anxiety-depressive disorders in patients with arterial hypertension associated with coronary heart disease. // Journal of Hypertensionю – 2011. – Vol. 29, Issue p. e275. – P.p. 15.407. (21st European Meeting on Hypertension and Cardiovascular Prevention. – Milan, Italy. – June 17-20, 2011)

July 13-18  2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Dugina J., Epstein O., Zhavbert E., Ertuzun I.  A NOVEL ANTIBODY-BASED
MEDICINE AMELIORATES LEARNING AND MEMORY DEFICITS IN AMYLOID b RAT MODEL OF ALZHEIMER’S DISEASE. // 17th World Congress of Basic and Clinical Pharmaclogy. – Cape Town, South Africa. – Jily 13-18, 2014. – Vol.155,
Supl.1. – P.174-175
Proproten-100
Proproten-100® is a drug to treat alcoholism.
9 Congresses and conferences

Proproten-100

Proproten-100® is a drug to treat alcoholism.
Information about the preparation

Date
Conference name
Address
Thesises
June 24-28 2003
6th congress of the European Association for Clinical Pharmacology and Therapeutics
Istanbul, Turkey

Voronina T.A., Molodavkin G.M., Krylov E.N., Dugina J.L., Sergeeva S.A., Epstein O.I. Anxiolytic and Antidepressant Action of Proproten: Experimental and Clinical Study. // Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. – Istanbul. – June 24-28, 2003. – P.100

November 19-21  2003
4th International Forum on Mood and Anxiety Disorders
Monte-Carlo, Italy
Voronina T.A., Molodavkin G.M., Dugina J.L., Sergeeva S.A., Epstein O.I. Anxiolytic activity of proproten: involvement of GABA in this effect. // International Journal of Psychiatry in Clinical Practice. – 2003. – Vol.7, №4. – P.319 (4 th International Forum on Mood and Anxiety Disorders. – Monte Carlo. – November 19-21, 2003.).
August 1-6  2004
8th World Congress on Clinical Pharmacology & Theurapetics Incorporating the Annual Scientific Meeting of ASCEPT
Brisbane (Australia)

Epstein O.I., Voronina T.A., Dugina J.L., Martyushev-Poklad A.V., Sergeeva S.A. Proproten, a novel antianxiety agent with broad-spectrum psychotopic activities. // Clinical and Experimental Pharmacology and Physiology. – 2004. – Vol.31, Suppl.1. – A.72 (8th World Conference on Clinical Pharmacology and Therapeutics. Incorporating the Annual Scientific Meeting of ASCEPT. – Brisbane, Australia. – August 1-6, 2004.).

October 9-13  2004
17th European College Neuropsyhopharmacology congress
Stockholm, Sweden
Romanova G.A., Sergeeva S.A., Voronina T.A., Epstein O.I., Dugina J.L., Barskov I.V. Proproten, ultra-low doses of antibodies to S-100 protein, reduced brain damage in photochemically-induced photothrombosis. // European Neuropsychopharmacology. – 2004. – Vol.14, Suppl.3. – S.332 (17th Congress of the European College of  Neuropsychopharmacology. – Stockholm, Sweden. – October 9-13, 2004.).
November 10-13  2004
World Psychiatry Association International Congress "Treatments in psychiatry: an update".
Florence, Italy

Vetlugina T.P., Ivanova S.A., Bokhan N.A., Sergeyeva S.A., Epstein O.I. Antibodies to brain-specific S-100 protein in patients with alcoholism treated with proproten. // World Psychiatry. – 2004. – Vol.3, Suppl.1. – P.308 (World Psychiatric Association International Congress "Treatments in psychiatry: an update". – Florence, Italy – November 10-13, 2004).

June 25-29  2005
VII Congress of the European Association for Clinical Pharmacology and Therapeutics
Poznan, Poland
Dugina J.L., Martyushev-Poklad A.V., Epstein O.I., Sergeeva S.A. Results of a clinical study of proproten efficacy and safety in anxiety disorders. // Basic & Clinical Pharmacology & Toxicology. – 2005. – Vol.97, Suppl.I. – P.33-34 (7th Congress of the European Association for Clinical Pharmacology and Therapeutics. – Poznan, Poland. – June 25-29, 2005.).
August 8-11 2005
10th Anniversary Drug Discovery Technology & Development
Boston, United States
September 10-15  2005
XIII World Congress of Psychiatry
Cairo, Egypt

Martyushev-Poklad A., Dugina J., Epstein O., Sergeeva S. A novel antibody anxiolytic: results of short controlled clinical trials. // XIII World congress of psychiatry. – Cairo, Egypt. – September 10-15, 2005.– P.432

October 22-26  2005
European College of Neuropsychopharmacology Conference
Amsterdam, Netherlands
Dugina J.L., Voronina T.A., Martyushev-Poklad A.V., Sergeeva S.A., Heifets I.A., Epstein O.I. The anticonflict and antidepressant-like effects of proproten are serotonin dependent. // 18th Europen Congress Neuropsychopharmacology. – Amsterdam, Netherlands. – October 22-26, 2005. – P.538
Divaza
Divaza®: a modern-day nootropic and vasoactive drug with a novel mechanism of action intended to treat chronic cerebrovascular disorders.
1 Congresses and conferences

Divaza

Divaza®: a modern-day nootropic and vasoactive drug with a novel mechanism of action intended to treat chronic cerebrovascular disorders.
Information about the preparation

Date
Conference name
Address
Thesises
July 13-18 2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa

Dugina J., Epstein O., Zhavbert E., Ertuzun I.  A NOVEL ANTIBODY-BASED MEDICINE AMELIORATES LEARNING AND MEMORY DEFICITS IN AMYLOID b RAT MODEL
OF ALZHEIMER’S DISEASE.
// 17th World Congress of Basic and Clinical
Pharmaclogy. – Cape Town, South Africa. – Jily 13-18, 2014. – Vol.155,
Supl.1. – P.174-175

Dietressa
Dietressa® is an innovative OTC drug for weight management.
1 Congresses and conferences

Dietressa

Dietressa® is an innovative OTC drug for weight management.
Information about the preparation

Date
Conference name
Address
Thesises
July 13-18 2014
17th World Congress of Basic and Clinical Pharmacology.
Cape Town, South Africa

Gurianova N., Bugaeva L., Dugina J., Petrov V., Epstein O. THE
EFFICACY OF DIETRESSA, A NOVEL ANTI-OBESITY DRUG IN WEIGHT LOSS OF MICE FED WITH HIGH-FAT DIET.
// 17th World Congress of Basic and Clinical
Pharmaclogy. – Cape Town, South Africa. – Jily 13-18, 2014. – Vol.155,
Supl.1. – P.248

Brizantin
Brizantin® is a nicotine-free drug with a complex mechanism of action aimed at alleviating symptoms of smoking withdrawal and reducing smoking addition.
1 Congresses and conferences

Brizantin

Brizantin® is a nicotine-free drug with a complex mechanism of action aimed at alleviating symptoms of smoking withdrawal and reducing smoking addition.
Information about the preparation

Date
Conference name
Address
Thesises
July 17-23  2012
6th European Congress of Pharmacology
Granada, Spain
Dugina J., Tolstikova T., Kheifets I., Epstein O. Efficacy of a novel combination drug in the treatment of nicotine-associated behavioral effects in mice. // 6th European Congress of Pharmacology EPHAR 2012. – Granada, Spain. – July 17-23, 2012. – P469
Arthrofoon
Arthrofoon® is specially designed as a long-term therapy for chronic inflammatory joint diseases, and as an aid in recovery after joint disease exacerbations.
8 Congresses and conferences

Arthrofoon

Arthrofoon® is specially designed as a long-term therapy for chronic inflammatory joint diseases, and as an aid in recovery after joint disease exacerbations.
Information about the preparation

Date
Conference name
Address
Thesises
October 6-11 2002
Joint Meeting of the International Cytokine Society (ICS), the International Society for Interferon and Cytokine Research (ISICR), the European Cytokine Society (ECS) and Society for Leukocyte Biology (SLB)
Torino, Italy
Martyushev A.V., Sherstoboev E.Ju., Pashinskiy V.G., Sergeeva S.A., Epstein O.I. Anti-cytokine antibodies in ultralow doses (ULD) regulate cytokine expression: experimental and clinical aspects. // Journal of interferon and Cytokine research. – Vol.22. – Suppl.1. – 2002. – S. 122 (Abstracts from the Joint Meeting of the International Society for Interferon and Cytokine Research (ISICR), the International Cytokine Society (ICS), the Society for Leukocyte Bijlogy (SLB), and the European Cytokine Society (ECS). Cytokines and Interferons 2002 Turin, Italy.
June 24-28 2003
6th congress of the European Association for Clinical Pharmacology and Therapeutics
Istanbul, Turkey

Petrov V.I., Babaeva A.R., Tcherevkova E.V., Martyushev-Poklad A.V., Sergeeva S.A., Epstein O.I. Artrofoon in Treatment of Rheumatoid Arthritis Patients: A Pilot Randomized Clinical Study. // Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. – Istanbul. – June 24-28, 2003. – P.99

August 2-6 2003
6th congress on Inflammation
Vancouver, Canada
Thesis 1

Martyushev-Poklad A.V., Pashinskiy V.G., Sergeeva S.A., Dygai A.M., Epstein O.I. Anti-inflammatory effects of oral ultra-low doses of anti-TFNα: experimental findings. // Inflammation Research. – 2003. – Vol.52, Suppl.2 – S.158 (6th World Congress on Inflammation. – Vancouver, Canada. – August 2-6, 2003.).

 Thesis 2

Martyushev-Poklad A.V., Babaeva A.R., Tcherevkova E.V., Sergeeva S.A., Epstein O.I., Petrov V.I. Artrofoon (oral ultra-low doses of anti – TNFα) in rheumatoid arthritis: primary clinical findings. // Inflammation Research. – 2003. – Vol.52, Suppl.2 – S.159 (6th World Congress on Inflammation. – Vancouver, Canada. – August 2-6, 2003.).

April 20-23  2004 
The British Society for Rheumatology. Annual Meeting
Edinburgh, Scotland
Petrov V.I., Babayeva A.R., Dugina J.L., Martyushev-Poklad A.V., Kachanova M.V., Tcherevkova E.V., Epstein O.I., Sergeeva S.A. Efficacy of artrofoon in rheumatoid arhtritis: results of a six-month open-label study. // Rheumatology. – 2004. – Vol.43, Suppl.2. – P. ii47 (British Society for Rheumatology. Annual Meeting. – Edinburgh, Scotland. – April 20-23, 2004 and British Health Professionals. Spring Meeting. – Edinburgh, Scotland. – April 21-23, 2004.).
June 9-12  2004
Annual European congress of rheumatology
Berlin, Germany
Petrov V.I., Babayeva A.R., Dugina J.L., Martyushev-Poklad A.V., Kachanova M.V., Tcherevkova E.V., Epstein O.I., Sergeeva S.A. An open-label, comparative trial of artrofoon and diclofenac in rheumatoid arthritis: clinical efficacy and effect on serum cytokines. // Annals of the Rheumatic Diseases. – 2004. – Vol.63, Suppl.1. – P.254 (Annual European Congress of Rheumatology. – Berlin, Germany. – June 9-12, 2004.). 
August 1-6  2004
8th World Congress on Clinical Pharmacology & Theurapetics Incorporating the Annual Scientific Meeting of ASCEPT
Brisbane (Australia)

Dugina J.L., Petrov V.I., Babayeva A.R., Martyushev-Poklad A.V., Tcherevkova E.V., Kachanova M.V., Epstein O.I., Sergeeva S.A. Artrofoon, oral ultra low doses of antibodies to TNF-α in rheumatoid arthritis. // Clinical and Experimental Pharmacology and Physiology. – 2004. – Vol.31, Suppl.1. – A.66 (8th World Conference on Clinical Pharmacology and Therapeutics. Incorporating the Annual Scientific Meeting of ASCEPT. – Brisbane, Australia. – August 1-6, 2004.).

June 25-29  2005
VII Congress of the European Association for Clinical Pharmacology and Therapeutics
Poznan, Poland
Digina J.L., Petrov V.I., Babayeva I.R., Martyushev-Poklad A.V., Kostryukova I.V., Tcherevokova E.V., Kachanova M.V., Epstein O.I., Sergeeva S.A. Artrofoon, oral ultra-low doses of antibodies to TNF-alpha, is effective both in rheumatoid arthritis and osteoarthritis. // Basic & Clinical Pharmacology & Toxicology. – 2005. – Vol.97, Suppl.I. – P.95 (7th Congress of the European Association for Clinical Pharmacology and Therapeutics. – Poznan, Poland. – June 25-29, 2005.).
July 2-7  2006
15th World Congress of Pharmacology
China
Dugina J., Martyushev-Poklad A., Petrov V., Babayeva A., Kostrukova I., Klimenko K., Kachanova M., Epstein O., Sergeeva S. Artrofoon, an oral anti – TNF alpha therapeutic, is effective in both rheumatoid arthritis and osteoarthritis: results of clinical trials. // Acta Pharmacologica Sinica. – 2006. – Vol.27, Suppl.1. – P.271 (15th World Congress of Pharmacology. – Beijing, China. – July 2-7, 2006.).
Anaferon
An innovative drug for the treatment and prevention of influenza. For sale in Vietnam.
3 Congresses and conferences

Anaferon

An innovative drug for the treatment and prevention of influenza. For sale in Vietnam.
Information about the preparation

Date
Conference name
Address
Thesises
July 7 – 12 2002 
XIVth World Congress of Pharmacology. The New Centry of Parmacology
Moscone Convention Center San Francisco, California

Marteushev A.V., Sherstoboyev E.Yu., Sergeeva S.A., Belskiy Yu.P., Dygai A.M.Goldberg E.D., Epshtein O.I. Ultralow doses of antibodies to interferon gamma (ULD anti – IFNγ) as a novel immunomodulator. // XIV World Congress of Pharmacology The New Century of Pharmacology, Abstract Volume. – July 7 – 12 2002 Moscone Convention Center San Francisco California – Pharmacologist. – Vol.44, №2 (Suppl.1). – 2002. – A 240

October 6-11 2002
Joint Meeting of the International Cytokine Society (ICS), the International Society for Interferon and Cytokine Research (ISICR), the European Cytokine Society (ECS) and Society for Leukocyte Biology (SLB)
Torino, Italy
Martyushev A.V., Sherstoboev E.Ju., Pashinskiy V.G., Sergeeva S.A., Epstein O.I. Anti-cytokine antibodies in ultralow doses (ULD) regulate cytokine expression: experimental and clinical aspects. // Journal of interferon and Cytokine research. – Vol.22. – Suppl.1. – 2002. – S. 122 (Abstracts from the Joint Meeting of the International Society for Interferon and Cytokine Research (ISICR), the International Cytokine Society (ICS), the Society for Leukocyte Bijlogy (SLB), and the European Cytokine Society (ECS). Cytokines and Interferons 2002 Turin, Italy.
July 13-18 2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Tarasov S., Gorbunov E., Myslivets M., Rodionova N., Epstein O. NOVEL
ANTIBODY-BASED BIOTECHNOLOGICAL APPROACH OF INFLUENZA MANAGEMENT:
SUMMARY OF PRECLINICAL AND CLINICAL STUDIES. // 17th World Congress of
Basic and Clinical Pharmaclogy. – Cape Town, South Africa. – Jily 13-18,
2014. – Vol.155, Supl.1. – P.230 
Impaza
An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Cambodia.
13 Congresses and conferences

Impaza

An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Cambodia.
Information about the preparation

Date
Conference name
Address
Thesises
July 7 – 12 2002 
XIVth World Congress of Pharmacology. The New Centry of Parmacology
Moscone Convention Center San Francisco, California

Smolenov I.V., Dygai A.M., Epshtein O.I., Borovskaya T.G., Sergeeva S.A., Goldberg E.D. Ultralow doses of antibodies to endothelial NOS (ULD anti-eNOS) are effective in erectile dysfunction. // XIV World Congress of Pharmacology The New Century of Pharmacology, Abstract Volume. – July 7 – 12 2002 Moscone Convention Center San Francisco California – Pharmacologist. – Vol.44, №2 (Suppl.1). – 2002. – A 167

June 24-28  2003
6th congress of the European Association for Clinical Pharmacology and Therapeutics
Istanbul, Turkey

Martyushev-Poklad A.V., Smolenov I.V., Petrov V.I., Dugina J.L., Sergeeva S.A., Epstein O.I. Impaza – a New Promising Remedy for Erectile Dysfunction: Placebo-Controlled Trial. // Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. – Istanbul. – June 24-28, 2003. – P.99

June 28-July 1 2003
2nd International Consultation on Erectile and Sexual Dysfunction
Paris, France
Thesis 1

Alaev Yu.G., Vinarov A.Z., Lokshin K.L., Spivak L.G., Sergeeva S.A. Safety and efficacy of impaza in patients suffering from erectile dysfunction (ED). // Progres en Urologie. – 2003. – Vol.13. – Sup. №2, №3. – P.27 (2nd International Consultation on Erectile and Sexual Dysfunctions. – Paris – June 28-July 1, 2003.).

Thesis 2

Mazo E., Gamidov S., Ovchinnikov R., Moufagued M., Martyushev-Poklad A. Impaza – a new effective agent for treatment of erectile dysfunction. // Progres en Urologie. – 2003. – Vol.13, №3, Suppl.2. – Р.12 (2nd International Consultation on Erectile and Sexual Dysfunctions. – Paris. – June 28-July 1, 2003.).

Thesis 3

Martyushev-Poklad A.V., Smolenov I.V., Sergeeva S.A., Epstein O.I. A novel drug for erectile dysfunctions based on ultra-low doses of antibodies: results of clinical trials. // Progres en Urologie. – 2003. – Vol.13, №3, Suppl.2.– P.12 (2nd International Consultation on Erectile and Sexual Dysfunctions. – Paris. – June 28-July 1, 2003.).

September 11-14 2003
8th Mediterranean Congress of Urology
Herakleion, Greece
Thesis 1

Mazo E., Gamidov S., Ovchinnikov R., Moufagued M. Impaza – first effective agent for induction of nitric oxide synthase for treatment of erectile dysfunction. // 8th Mediterranean congress of urology. – Heracleion, Greece. – September 11-14, 2003. – P.145

Thesis 2

Martyushev-Poklad A., Smolenov I., Sergeeva S., Epstein O. Efficacy of Impaza in erectile dysfunction: clinical trial. // 8th Mediterranean congress of urology. – Heracleion, Greece. – September 11-14, 2003. – P.147

November 16-19  2003
6th ESSM Congress of the European Society for Sexual Medicine
Istanbul, Turkey
Martyushev-Poklad A., Epstein O., Sergeeva S., Smolenov I. Efficacy of impaza in erectile dysfunction: Сlinical trials. // International Journal of Impotence Research. The Journal of Sexual Medicine. – 2003. – Vol.15, Suppl.6. – S.28 (6th Congress of the European Society for Sexual Medicine. – Istanbul, Turkey. – November 16-19, 2003.).
February 26-29  2004
4th World Congress on The Aging Mail.
Prague, Czech Republic
Martyushev-Poklad A.V., Petrov V.I., Sergeeva S.A., Epstein O.I. Impaza, a novel erectile dysfunction remedy: efficacy and impact on androgenic status. // The Aging Mail. – 2004. – Vol.7, №1. – P.55 (4th World Congress on The Aging Mail. – Prague, Czech Republic. – February 26-29, 2004.).
August 1-6 2004
8th World Congress on Clinical Pharmacology & Theurapetics Incorporating the Annual Scientific Meeting of ASCEPT
Brisbane (Australia)
Martyushev-Poklad A.V., Petrov V.I., Dugina J.L., Еpstein O.I., Sergeeva S.A. Impaza - a novel oral antibody drug for erectile dysfunction. // Clinical and Experimental Pharmacology and Physiology. – 2004. – Vol.31, Suppl.1. – A.124 (8th World Conference on Clinical Pharmacology and Therapeutics. Incorporating the Annual Scientific Meeting of ASCEPT. – Brisbane, Australia. – August 1-6, 2004.).
December 5-8  2004
7-th Congress of the European Society for Sexual Medicine
London, UK
Gamidov S., Mazo E., Ovchinnikov R. Combination of Impaza and inhibitors of phosphodiesterase type 5 - An alternative for treatment of erectile dysfunction. // The Journal of Sexual Medicine. – 2005. – Vol.2, Suppl.1. – P.38 (7th Congress of the European Society for Sexual Medicine. – London, UK. – December 5-8, 2004.).
June 12-16  2005
8th International Congress of Andrology
Seoul, Korea
Thesis 1

Martyushev-Poklad A.V., Mazo E.B., Gamidov S.I., Dugina J.L., Epstein O.I., Sergeeva S.A. Impaza, an oral antibody therapeutic for erectile dysfunction: benefits from mono- and combined therapy. // International journal of Andrology. – 2005. – Vol.28, Suppl.1. – P.49 (8th International Congress of Andrology. – Seoul, Korea. – June 12-16, 2005.).

Thesis 2

Martyushev-Poklad A.V., Petrov V.I., Dugina J.L., Epstein O.I., Sergeeva S.A. A novel oral antibody therapeutic for treatment of BPH: primary findings of a controlled clinical trial. // International journal of Andrology. – 2005. – Vol.28, Suppl.1. – P.116 (8th International Congress of Andrology. – Seoul, Korea. – June 12-16, 2005.).

June 17-22 2008


IBNS 17th Annual Meeting
US Virgin Islands
July 27-August 1  2008
The IXth World Conference on Clinical Pharmacology and Therapeutics
Quebec, Canada

Dugina J.L., Savelieva K.V., Sergeeva S.A., Epstein O.I. A Novel Antibody – based Therapeutic for Benign Prostate Hyperplasia: Results of a Randomized Clinical Trial. // The Canadian Journal of Clinical Pharmacology. – 2008. – Vol.15(3). – P.e432-e433. (IXth World Conference on Clinical Pharmacology and Therapeutics. – Québec City, Canada. – July 27-August 1, 2008.).

December 7-11  2008
13th World Congress of the International Society for Sexual Medicine
Brussels - Belgium
Zhavbert E.S., Kachanova M.V., Dugina J.L., Sergeeva S.A., Epstein O.I. Impaza therapeutic efficacy in men with erectile dysfunction depends on eNOS gene polymorphism. // The journal of Sexual Medicine. – 2008. – P.87 (Joint meeting of the European (ESSM) and International (ISSM) Societies for Sexual medicine. – Brussels, Belgium. – December 7-11, 2008.).
July 13-18  2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Dugina J., Epstein O., Zhavbert E., Ertuzun I.  A NOVEL ANTIBODY-BASED
MEDICINE AMELIORATES LEARNING AND MEMORY DEFICITS IN AMYLOID b RAT MODEL OF ALZHEIMER’S DISEASE.
// 17th World Congress of Basic and Clinical Pharmaclogy. – Cape Town, South Africa. – Jily 13-18, 2014. – Vol.155,
Supl.1. – P.174-175
Scientific platform
9 Congresses and conferences

Scientific platform

Date
Conference name
Address
Thesises
July 7 – 12 2002 
XIVth World Congress of Pharmacology. The New Centry of Parmacology
Moscone Convention Center San Francisco, California

1. Thesis

Epshtein O.I., Shtark M.B., Vorobyova T.M. Bipathy phenomen (BP): dynamized forms (DF) of a remedy modifies the remedy’s effects on co-administration. // XIV World Congress of Pharmacology The New Century of Pharmacology, Abstract Volume. – July 7 – 12 2002 Moscone Convention Center San Francisco California – Pharmacologist. – Vol.44,№2 (Suppl.1). – 2002. – A 166

2. Thesis

Kovalyova V.L., Zak M.S., Sergeeva S.A., Epstein O.I. Antitussive activity of antibodies in ultralow doses. // XIV World Congress of Pharmaco- logy The New Century of Pharmaco- logy, Abstract Volume. – July 7 – 12 2002 Moscone Convention Center San Francisco California – Pharmacologist. – Vol.44, №2 (Suppl.1). – 2002. – A 227-228

November 30-December 3, 2004
IBC’s Second Annual International Conference Antibody Therapeutics Advances and Strategies for the Development of the Antibody Therapeutic Pipeline
San Diego,CA

1. Thesis

Martyushev-Poklad A. Therapeutic antibodies in ultra-low doses for peroral use: examples of successful development. // IBC's 2nd Annual International Conference Antibody Therapeutics Advances and Strategies for the Development of the Antibody Therapeutic Pipeline. – Sheraton San Diego Hotel & Marina, San-Diego, CA. – November 30-December 3, 2004.

2. Thesis

Dugina J. Oral ultra-low dose antibody therapeutics: frequently asked questions. // IBC's 2nd Annual International Conference Antibody Therapeutics Advances and Strategies for the Development of the Antibody Therapeutic Pipeline. – Sheraton San Diego Hotel & Marina, San-Diego, CA. – November 30-December 3, 2004.

3. Thesis
Sergeeva S. Antibodies in ultra-low doses for oral use: evidences, pitfalls and promises. // IBC's 2nd Annual International Conference Antibody Therapeutics Advances and Strategies for the Development of the Antibody Therapeutic Pipeline. – Sheraton San Diego Hotel & Marina, San-Diego, CA. – November 30-December 3, 2004.

March 15-16, 2005
Drug discovery technology Europe 2005 Conference
London, England
Martyushev-Poklad A.V. Therapeutic antibodies in ultra-low doses for peroral use: four examples of successful development. // Drug Discovery Technology. – London, UK, Europe. – March 15-16, 2005. – P.48 
November 7-9, 2005
The 11th Annual International Conference on Partnership BIO-EUROPE 2005
Dresden, Germany
Zilberman Y. Materia Medica Holding, Antibodies, Drug Development, Biopharmaceuticals. // 11th Annual International Partnering Conference Bio-Europe 2005. – Congress Center, Dresden, Germany. – November 7-9, 2005.
February 18-21, 2013
5th International Conference on Drug Discovery & Therapy
Dubai, UAE
Tarasov S.А. Novel Opportunity for Pharmacological Regulation of Endogeneous Targets by Antibodies in Release Active Form. // 5th International Conference on Drug Discovery & Therapy (5th ICDDT). – Dubai, UAE. – February 18-21, 2013. – P.83
March 18-20, 2013
BIT’s 5th Annual International Congress of Antibodies-2013
Hangzhou, China
Tarasov S. Polyclonal Antibodies in Release-active Form as Novel Therapeutic Agents. // BIT’s 5th International Congress of Antibodies-2013. BIT’s 5th Annual World Congress of Vaccine-2013. – Hangzhou, China. – March 18-20, 2013. – P.085
Jily 13-18, 2014
17th World Congress of Basic and Clinical Pharmaclogy.
Cape Town, South Africa
Epstein O., Tarasov S., Dugina J. Repeated serial concentration
reduction: disregarded technology.
// 17th World Congress of Basic and
Clinical Pharmaclogy. – Cape Town, South Africa. – Jily 13-18, 2014. –
Vol.155, Supl.1. – P.144
September 29-October 01
3rd International Conference and Exhibition on Clinical & Cellular Immunology
Baltimore, USA
Gavrilova E., Gorbunov E., Borshcheva A., Natalia Guryanova N, Tarasov S. Application of drugs based on release-active antibodies as immunotherapy agents.// 3rd International Conference and Exhibition on Clinical & Cellular Immunology. - DoubleTree by Hilton Baltimore-BWI Airport, USA. - September 29-October 01, 2014. – Vol. 5. – P. 62
Jule 22-25, 2015
Global Biotechnology Congress
Boston, MA, USA.
Elena S. Don, Vyacheslav V. Grechenko, Suzanna E. Pokhil, Alena A. Borsheva, Darya V. Barykina, Marina V. Nikiforova, Evgeny A. Gorbunov, Sergey A. Tarasov RELEASE-ACTIVE ANTIBODIES ARE INNOVATIVE ANTIBODIES-BASED DRUGS: NEW WAY TO QUALITY ASSESSMENT. // Global Biotechnology Congress. – Boston, MA, USA. – Jule 22-25, 2015. – P.60